Investigation of new synthetic compounds: 4-(methyl sulfanyl)phenyl-1,3,4-thiadiazol-2-amine and 1-methyl-[4-(methyl sulfanyl)phenyl]-1,3,4-thiadiazol-2-amine, for anti-cancerous activity and for p53 anti-cancer gene expression on glioblastoma cell cultures (LN-229)

Title : Investigation of new synthetic compounds: 4-(methyl sulfanyl)phenyl-1,3,4-thiadiazol-2-amine and 1-methyl-[4-(methyl sulfanyl)phenyl]-1,3,4-thiadiazol-2-amine, for anti-cancerous activity and for p53 anti-cancer gene expression on glioblastoma cell cultures (LN-229)

Abstract:

Glioblastoma Multiforme (GBM) is a stage IV brain tumour is complex and deadly diseases. There is no promising therapeutic applications for GBM, and so many drugs are developed, and screened in pre- clinical/clinical tests. To understand the mechanism of GBM cancer causes the cell lines models were considered, of which LN-229 is used in the present study. There exists newly synthesized thiadiazole derivatives, namely, 4-(methyl sulfanyl) phenyl-1,3 ,4-thiadiazol-2 amine and 1- methyl- [4-(methyl sulfanyl) phenyl]-1,3,4-thiadiazol-2-amine, that needs to be tested for their anti-cancer activity. The research gap of not using GBM cell lines extensively for drug screening are examined for current studies. Hence, LN-229 is used as in vitro model to assess the anti-cancer activity of the given thiadiazole derivatives. It has to be noted that this is a small-scale study involving few samples, trying to determine only the IC50 value in case of LN-229 cells. The feasibility of the study outcomes is notable enough to consider for further analysis. Hence, there is cancer gene expression carried out to determine upregulation/downregulation of genes such as TP53, and EGFR, mutated in cancer cells. So the MTT assay performed for cell ability testing and RT-qPCR for gene expression analysis were employed for the current study. Overall, the aim is to integrate drug screening with disease of interest. The present studies confirms for new synthetic thiadiazole compounds are proven to have potential anti- cancer activity against GBM cell line LN-229, with upregulation of TP53 gene and downregulation of EGFR gene which promises the experimental design for anticancer chemotherapeutics.

Key words: Glioblastoma Multiforme, LN228 cell lines, P53, EGFR, Thiadiazol-derivatives.

Biography:

Prabha Muddobalaiah is an accomplished academician with a diverse research background in medical neuroscience, focusing on brain tumors and neurodegeneration, as well as cell/molecular neurochemistry, including neural stem cells and hydrolases. She holds an MSc in Biochemistry from Central College (1996) and a PhD in Biochemistry from Bangalore University and NIMHANS (2005). Prabha also completed a visiting fellowship at NCBS in 2006 and a postdoctoral fellowship at MCBL, IISc from 2007 to 2008. With over 24 years of research experience, including a PhD and postdoctoral training, she has spent 15 years in academia, with 7 years as an Assistant Professor and currently serving as an Associate Professor since 2017. She has delivered 8 invited talks and received around 30 invitations to speak abroad, published 20 research papers (18 as the first author), and served as an invited reviewer for journals like *Journal of Neurochemistry* and *Cancer Biomarkers*. Prabha is also a life member of several academic organizations, including IAN and SNCI India, and is an editorial member of three journals. Her contributions have earned her several prestigious awards, including the Bharat Shiksha Gaurava Puraskar, the Excellence for Best Educationist Award in 2022, and the Eminent Educationist of India Award by KTK Foundation, New Delhi, in November 2022. She also received the NPTEL Domain Star award in Biotechnology-Biosciences in 2022, earning six silver medals and an Elite certificate, and was recognized with the Women Researcher Award at the International Scientist Awards on Engineering, Science, and Medicine in November 2022.